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Abstract
Background: Some studies show that the incidence of Lyme borreliosis is increasing in different European
countries. In order to evaluate if this is also the case in Belgium, different data sources were consulted to describe
the epidemiology of Lyme borreliosis in the country during the last decade.
Methods: Data from two databases were analyzed for the time period 2003–2010 and 2003–2012 for respectively:
the registration of minimal clinical data from Belgian hospitals (principal and secondary diagnosis), and a sentinel
laboratory network reporting positive laboratory results.
Results: The number of hospitalized cases per year remained stable between 2003 and 2010, ranging from 970
(in 2008) to 1453 (in 2006), with a median of 1132.5 cases per year. Between 2003 and 2012, yearly fluctuations in
the number of positive tests were reported by the sentinel laboratory network (with a minimum of 996 positive
tests in 2007 and a maximum of 1651 positive tests in 2005), but there is no increasing trend over the study period
(median = 1200.5 positive tests per year). The highest incidence rates of hospitalization and the highest reported
incidence of positive laboratory results are registered in the provinces of Luxemburg, Limburg, Flemish Brabant and
Antwerp, with a typical seasonal pattern (peak in September). The age groups affected most are those from 5 to
14 years and 45 to 69.
Conclusion: Based on hospital records and laboratory results, no increasing trend in Lyme disease was observed
over the 2003–2012 period in Belgium. These results are in line with the stable incidence of erythema migrans
reported by a sentinel network of general practitionners between 2003 and 2009. Multi-source surveillance of
vector-borne diseases should be further implemented.
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Background
Lyme borreliosis is a multisystemic disease caused by
spirochaetes belonging to the Borrelia burgdorferi sensu
lato complex [1]. It is the most common tick-borne dis-
ease in North America and in Europe [2]. Historically,
many syndromes, among which Bannwarth syndrome
(painful radiculitis, cranial neuritis and lymphocytic
meningitis) were reported since 1883 in Europe, and can
retrospectively be designated as manifestations of Lyme
borreliosis [2]. The spirochaete responsible for the dis-
ease was first discovered in ticks by W. Burgdorfer and
collaborators in 1982, and afterwards named Borrelia
burgdorferi sensu stricto [1]. It is a complex which com-
prises at least 19 genospecies [3, 4], and several of them
are pathogenic to humans. The primary tick vector of
the spirochaete in Europe is Ixodes ricinus [2, 3], and
the main responsible of Borrelia transmission to humans
are tick nymphs. They quest most actively from spring
to autumn in microenvironments with more than 85 %
relative humidity, such as deciduous or mixed woodland,
as well as suburban and urban environments and road-
sides [5].
The clinical manifestations in humans can be divided
into three stages: early, early disseminated and late dis-
seminated Lyme borreliosis [2, 6]. Early Lyme borreliosis
(days to weeks) is most often characterized by a typical
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erythema migrans starting 3 to 30 days (typically after 7
to 14 days) after a tick bite. A borrelial lymphocytoma is
rarely diagnosed, and described as a bluish red tumor-like
skin infiltrate, often located at the earlobe or at the nipple.
When the infection is untreated, the spirochete can dis-
seminate and cause early disseminated Lyme borreliosis
(weeks to months after the tick bite). Its manifestations
include early neuroborreliosis, Lyme arthritis, multiple
erythema migrans [7] or more seldom myocarditis with
atrioventricular block. Finally, late manifestations of Lyme
borreliosis can occur months to years after the infection,
such as acrodermatitis chronica atrophicans, untreated
Lyme arthritis, neuroborreliosis and possible autoimmune
phenomena [2]. The vast majority of patients respond well
to antibiotic treatment, with drug type, dose, route (oral
or intravenous) and duration varying with the symptoms
and the stage of the disease.
The diagnosis of Lyme borreliosis is mainly based on
clinical symptoms (presence of erythema migrans, gener-
ally found in 60 to 80 % cases) and serological tests [2, 5].
Serological testing is recommended only 6 to 8 weeks after
onset, and only in case of atypical, disseminated or late
manifestations of the disease [2]. However, in the absence
of clinical symptoms, the presence of anti-Borrelia anti-
bodies does not necessarily indicate the presence of an ac-
tive infection. Indeed, 4 to 20 % of the normal Western
European population have detectable antibodies, most
likely due to a (asymptomatic) Borrelia infection in the
past. International guidelines recommend thus not to test
for antibodies against Borrelia when the suspicion on
Lyme borreliosis is low [2]. Furthermore, the duration of
anti-Borrelia antibodies persistence in the human body is
unknown. Reinfection in patients successfully treated by
antibiotics has been described in the literature [8].
Some authors suggest that Lyme disease will become
an important health concern in the coming years, espe-
cially in light of climate change predictions, which may
impact on tick density [5]. Indeed, the annual number of
Lyme borreliosis is increasing in some European coun-
tries (among others the Netherlands [9, 10], the United
Kingdom [11], Hungary [12]), although not in others,
like Germany [13], France [14] and Switzerland [15]. An
increase in consultations and hospital admissions for
Lyme borreliosis has also been described between 1994
and 2009 in the Netherlands, a neighboring country of
Belgium [9, 10]. Concerns have thus arisen regarding the
evolution of Lyme borreliosis in Belgium during the last
decade, where some seroprevalence studies have been
carried out in the past [1, 6, 16]. A study on the inci-
dence of the disease based on data from a sentinel net-
work of general practitioners did not show any increase
of tick bite or erythema migrans incidence between the
years 2003–2004 and 2008–2009 [17]. In the present
study, we used routinely collected surveillance data to
describe the epidemiology of Lyme disease in Belgium
during the last ten years (2003–2012) and confirm or in-
validate the stability described by the sentinel network of
general practitioners [17].
Methods
Data collection
Two different data sources were used to collect data on
Lyme borreliosis epidemiology in Belgium. Firstly, the
number of hospitalizations, through the registration of
minimal clinical data was collected to evaluate the bur-
den of early disseminated and late manifestation of the
disease. Secondly, data on positive results of laboratory
tests reported by a sentinel network of laboratories were
analyzed.
Since 1990, the Belgian Ministry of Health (federal
public service Health, Food chain safety and Environ-
ment) collects compulsorily registered data (registration
of minimal clinical data, RMC) from every general hos-
pital in Belgium [18]. For each patient discharged, the
physician has to fill in a standardized form summarizing
medical records, and specifying all diagnosis. Data are
then encoded following the International Classification
of Diseases (ICD-9). In the ICD-9 classification, all Lyme
borreliosis manifestations are grouped under the same
code (088.81). We are thus unable to distinguish the
type of complication leading to the hospitalization of the
patient. At the time of this study, data were available until
2010. We therefore used RMC data (for all hospitalization
wards) from 2003 to 2010, with Lyme borreliosis as princi-
pal and secondary diagnosis.
Since 1983, a sentinel laboratory network (SNL), coor-
dinated by the Scientific Institute of Public Health
(WIV-ISP) collects positive laboratory results on about
35 infectious diseases [19, 20], including Lyme borrelio-
sis since 1987. The laboratories participate in this net-
work on a voluntary basis. The absolute number of
participating laboratories decreased over time due to
fusions between laboratories, but the proportion of
tests covered by the network remained globally stable.
The network covers around 50 % of all laboratory tests
carried out in Belgium (Berger N., unpublished obser-
vations). Each participating laboratory weekly reports
the number of laboratory confirmed borrelia cases to
the WIV-ISP, with information on test date, place of
residence, gender and date of birth of the patient. A
search for duplicates is performed within a calendar
year, considering that a reinfection may occur after a
one-year period.
The type of positive Lyme borreliosis test collected by
the SLN changed over the study period (2003–2012). In-
deed, a change in the NIHDI (National Institute for Health
and Disability Insurance) reimbursement of serological
tests occurred in 2008 in Belgium. Before 2008, only the
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ELISA screening benefited from a social security reim-
bursement. Since 2008, patients with a positive ELISA can
benefit from a refund of the immunoblot assay to confirm
ELISA screening. In our SLN database, data before 2008
contain thus the positive ELISA screening results. Since
2008, only positive blot assays (confirmation) are reported.
Data analysis
RMC and SLN data were analyzed in terms of time,
place and individual characteristics of the cases.
The geographical distribution was assessed by prov-
ince, based on the address of the case, not the place of
tick bite. For calculation of relative proportions (re-
ported incidences), the number of cases was divided by
the 2010 population of each province.
Reported cumulative incidences were compared at the
provincial level throughout different time periods, using
a non-parametric Wilcoxon test. RMC data were divided
into two equal periods (2003–2006 and 2007–2010) to
check the influence of a possible better knowledge of the
disease at the end of the decade. The most recent period
was then divided into two smaller time periods, and data
were compared with each other. SLN data were divided
into 2003–2007 and 2008–2012 periods, because of the
laboratory test change, which occurred in 2008. Data from
the most recent period were then compared between two
smaller time periods.
All graphs and analyses were performed using SAS
Enterprise Guide Software, version 5.1.
Results
Figures 1 and 2 present the number of hospitalizations
per year between 2003 and 2010, and the number of
positive tests per year between 2003 and 2012, respect-
ively. No increasing trend is observed during the study
period, with a number of hospitalizations ranging be-
tween a minimum of 970 in 2008 and a maximum of
1453 in 2006 (median = 1132.5 cases per year), and a
number of SLN positive tests fluctuating between 996
in 2007 and 1651 in 2005 (median = 1200.5 positive
tests per year).
The number of hospitalizations and the number of posi-
tive tests by month follow a seasonal pattern, with a min-
imal number of cases during the winter, a gradual increase
during the spring and summer periods, and a maximum
peak at the end of the summer and during the autumn
(cumulative value for RMC: n = 1462 in September; SLN:
n = 1794 in August), Figs. 3 and 4.
The distribution of the number of hospitalizations by
province identifies Luxemburg, Limburg and Antwerp as
the provinces reporting more hospitalizations for Lyme
borreliosis (Fig. 5). The cumulative incidence for the
period 2003 to 2010 was 228.8 hospitalizations/100 000
inhabitants for Luxemburg, 221.1 for Limburg and 153.5
for Antwerp. No significant changes were observed in
the number of hospitalizations between the 2003–2006
and 2007–2010 periods (p = 0.78), and between the
2007–2008 and 2009–2010 periods (p = 0.94). In propor-
tion to their respective population, the most positive
tests for Lyme borreliosis reported by the SLN were
for patients from the provinces Luxemburg, Flemish
Brabant and Antwerp (Fig. 6). The respective reported
cumulative incidences/100 000 inhabitants for the
period 2003–2012 was 508.5 for Luxemburg, 301.2 for
Flemish Brabant and 172.0 for Antwerp. A Wilcoxon
test applied to all reported cumulative incidences by
Fig. 1 Number of hospitalizations for Lyme borreliosis (principal and secondary diagnosis) by year, 2003–2010, Belgium
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province neither showed significant changes between the
2003–2007 and 2008–2012 periods (p = 0.96), nor be-
tween the 2009–2010 and 2011–2012 periods (p = 0.75).
Men were slightly more likely to be hospitalized than
women (58 %) and to have a positive serology result
(52 %). Most hospitalized patients were either 5–9 years
old children, or 45–69 years old adults, similar to the
age groups presenting the most positive laboratory tests
(5 to 14 years old children and adults aged 50 to
69 years). The age and gender distribution are compar-
able over the time period (data not shown).
Discussion
Lyme disease is becoming a “hot topic” in Western coun-
tries. In Europe, an increase in Lyme borreliosis has been
described in some countries, but not in others [5]. This is
also the case in the countries neighboring Belgium. The
Netherlands report an increase in consultations and
hospital admissions for Lyme borreliosis between 1994
and 2009 [9, 10]. Eastern Germany, on the other hand,
observes a decrease in Lyme borreliosis between 2009
and 2012 [13]. French reports show no increase in hospi-
talizations between 2004 and 2009, and also a stability in
Fig. 2 Number of Lyme borreliosis positive tests reported by the sentinel laboratory network, by year, 2003–2012, Belgium
Fig. 3 Number of hospitalizations for Lyme borreliosis, by month, 2003–2010, Belgium. Box plot: The mean and median annual number of cases
are presented by month. The length of the box represents the interquartile range (the distance between the 25th and the 75th percentile). The
horizontal line in the box represents the median, and the diamond, the mean. The wiskers extend to the group minimum and maximum value
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yearly Lyme borreliosis incidence rate (data from the gen-
eral practitioners sentinel network) between 2009 and
2012 [14]. Switzerland describes a stable reported inci-
dence between 2008 and 2011 [15]. However, comparisons
within and between countries need to be looked at with
caution, as surveillance methodology varies by country
and other factors might explain some variations. For ex-
ample in Belgium, a gradual increase in the number of
Lyme borreliosis positive tests was observed during the
beginning of the nineties, following the introduction of
ELISA test reimbursement.
In Belgium, surveillance of Lyme disease occurs through
a sentinel network of laboratories (SNL) reporting the
number of positive laboratory tests since 1987 [21]. The
reliability of the network is based on a stable participation
of laboratories, covering around 50 % of all Lyme borrelio-
sis tests carried out in Belgium (Berger N., unpublished
observations), with weekly automatic extraction of data
Fig. 4 Number of positive laboratory tests for Lyme borreliosis, by month, 2003–2012, Belgium. Box plot: The mean and median annual number
of positive tests are presented by month. The length of the box represents the interquartile range (the distance between the 25th and the 75th
percentile). The horizontal line in the box represents the median, and the diamond, the mean. The wiskers extend to the group minimum and
maximum value
Fig. 5 Cumulative incidence of hospitalizations for Lyme borreliosis by 100 000 inhabitants, by province, 2003–2010, Belgium
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for more than 70 % of participating laboratories. The
network allows to follow trends in incidence of labora-
tory confirmed tests, but this is only a partial picture of
the incidence of the disease. In the context of increas-
ing incidence of Lyme borreliosis in some European
countries, the routine surveillance data were validated
with information collected through the registration of
minimum clinical (RMC) data from the hospitals.
Both data sources converge to the same result: we do
not observe any increase in Lyme borreliosis in Belgium
during the study period. However, early clinical manifes-
tations of Lyme diseases, such as erythema migrans, are
not covered by these surveillance systems, since labora-
tory testing is not recommended in an early stage and
those manifestations do not require hospitalization. Yet,
results of two studies carried out by the Belgian sentinel
network of general practitioners did not show a signifi-
cant increase of the incidence rate of tick bites and ery-
thema migrans between 2003 and 2009 [17]. The
incidence of erythema migrans per 10,000 patients in
2003–2004 and in 2008–2009 was 8.32 and 9.02 respect-
ively (p > 0.05). Our SLN and RMC observations are
congruent with those clinical results.
Despite a global stable trend during the 2003–2010/
2003–2012 period, RMC and SLN data show yearly fluc-
tuations. Climate changes, with higher temperatures
during winter months and increased humidity, or the
presence of snow, impact on tick abundance and can ex-
plain some of these yearly variations [22, 23]. Further
studies are needed to explore the influence of climate on
Lyme disease in Belgium. The observed difference in
fluctuations over time between the SLN and RMC data
could be due to the fact that part of the hospitalizations
are due to late manifestations of Lyme borreliosis, which
may occur years after the tick bite. As RMC only pro-
vides the diagnosis without any precision regarding the
type of complication, we lack information to confirm or
invalidate this hypothesis.
Other factors than climate can also impact on Lyme dis-
ease incidence. The number of positive laboratory tests
depends on the prescription practice of physicians, which
is influenced by the reimbursement of tests, the physician’s
awareness of the disease, and individual insistence to be
tested. The latters are both influenced by various factors,
including media. However, during the study period, the
positivity rate of tests carried out by the SNL remained
stable (1.5 to 3.5 % of total tests) (WIV-ISP, unpublished
data), and no statistical difference was observed in inci-
dence of hospitalization and positive laboratory results
between the different time periods.
The monthly distribution of RMC and SLN cases fol-
lows a seasonal pattern, with a very small number of
cases during the winter, a gradual increase during the
spring and summer periods, and a maximum peak dur-
ing the end of the summer and the autumn. This is
congruent with Ixodes ricinus phenology [23]. The
number of nymphs collected in Belgium in 2009 and
2010 increased gradually during the spring, to reach a
maximum in July (in 2009) and in June (in 2010) [23].
The peak of the number of hospitalizations and positive
laboratory results is reached two to three months later,
which corresponds to the time of onset of the first
complications after a tick bite (early disseminated Lyme
borreliosis).
Fig. 6 Reported cumulative incidence of positive laboratory tests for Lyme borreliosis by 100 000 inhabitants, by province, 2003–2012, Belgium
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The highest cumulative incidence of hospitalizations,
and the highest incidence of inhabitants with positive la-
boratory tests during the study period are registered in
the province of Luxemburg. This province has different
geographical and climate characteristics compared to
other Belgian provinces that can influence on tick density,
with a higher proportion of forests, a higher altitude
(around 500 meters versus sea level) and a wetter and
colder climate, with snow during the winter. Other
provinces that are most affected by Lyme borreliosis
are Limburg, Antwerp and Flemish Brabant. These
provinces comprise small field and forest areas, alter-
nating with high densely populated urban areas, which
can also impact on tick density [22, 23]. Although the
geographical distribution presented here is based on
the place of residence of the patient, which is not neces-
sarily the place of infection, the distribution in our study is
in line with reported results of tick collection [23]. Indeed
in 2009 and 2010, high nymph densities were reported in
the provinces of Flemish Brabant (49.0 to 59.4 nymphs/
100 m2), Limburg (31.4 to 56.6 nymphs/100 m2) and
Luxemburg (12.1 to 17.2 nymphs/100 m2).
The individual characteristics of RMC and SLN cases
globally match the literature. A higher incidence in men
than in women has previously been described [17], and
could be due to a higher occupational risk, and also be
related to certain leisure activities. Regarding the age
distribution, the literature describes two groups mainly
affected: children from 5 to 14 years, and adults from 50
to 64 years [5], as observed in our study.
Although the two data sources used here report com-
parable results, they both have strengths and limita-
tions. The RMC database is based on compulsorily
registration of all Lyme borreliosis hospitalizations
from every general hospital in Belgium and is therefore
expected to be exhaustive. Its main limitations are the
delay needed to get the data, and a lack of precision re-
garding the symptoms, the ICD 9 code making no distinc-
tion between clinical manifestations. Moreover, since the
data collected represent both principal and secondary
diagnosis from all hospitalizations, the hospitalization inci-
dences presented in this study do not reflect the severity
of Lyme disease in Belgium but are rather used to appraise
its trends.
The sentinel laboratory network is considered to be
stable, and exists since more than 30 years. It nevertheless
comprises several limitations. Firstly, if the network is
representative at national level, its geographical reparti-
tion at provincial level is uneven. For example, the
coverage of East Flanders and Flemish Brabant is high
(between 80 and 90 %), whereas Namur, Liege and Limburg
have a lower coverage (below 50 %). The reported incidence
may thus be underestimated in the provinces with a lower
coverage. Secondly, it gives a partial picture of the
incidence, as laboratory tests are not recommended for
patients presenting with an erythema migrans. Thirdly,
a window period of undetectable antibodies should be
considered if the blood analysis occurs within the first
three weeks after the tick bite. Fourthly, laboratory
tests only confirm the presence of anti-Borrelia anti-
bodies, which does not necessarily means that the pa-
tient is suffering from Lyme disease: it could also be
due to a previous symptomatic or asymptomatic Borrelia
infection. Fifthly, the database may content some du-
plicates, as a patient is considered to be eligible for re-
infection after a one-year period. However, as the
database is repetitively used with the same parameters,
this phenomenon should not have any impact on its
global trend, which is of interest and regularly followed in
public health.
Finally, we must note that routine SLN monitoring
shows a new peak in positive tests for the year 2013, but
the positivity rate remains stable. Further follow-up and
surveillance remains essential.
Conclusion
In Belgium, the surveillance of Lyme borreliosis is per-
formed through three complementary sources: the WIV-
ISP sentinel laboratory network, hospitalization data and
a sentinel network of general practitioners. Those three
sources indicate that there is no increasing trend in
Lyme borreliosis during the 2003-2010/2012 period in
Belgium. As Lyme borreliosis is a complex disease, the
use of various data sources has to be maintained in the
future, in order to monitor the epidemiological evolution
of the disease and detect possible changes in trends. Fur-
thermore, surveillance of the vector in Belgium should
be strengthened. A new study involving the sentinel net-
work of general practitioners will start in 2015, to
follow-up on the incidence of tick bites and erythema
migrans. The automatic extraction of data from a unique
medical file in ambulatory medicine could facilitate clin-
ical surveillance of Lyme disease in future.
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